OncoMatch/Clinical Trials/NCT06655246
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Is NCT06655246 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including ziftomenib and imatinib mesylate for gastrointestinal stromal tumor (gist).
Treatment: ziftomenib · imatinib mesylate — In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: KIT mutation
Excluded: KIT t670x
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tyrosine kinase inhibitor (imatinib) — current or prior therapy
Documented disease progression on imatinib as current or prior therapy.
Cannot have received: prohibited medication, including investigational therapy
Exception: if received less than 14 days or within 5 drug half-lives before the first dose
Received a prohibited medication, including investigational therapy, less than 14 days or within 5 drug half-lives before the first dose of study intervention.
Lab requirements
Blood counts
Adequate organ function per protocol requirements.
Kidney function
Adequate organ function per protocol requirements.
Liver function
Adequate organ function per protocol requirements.
Cardiac function
Mean corrected QT interval (QTcF) greater than 470ms excluded; Left ventricular ejection fraction (LVEF) <50% excluded.
Adequate organ function per protocol requirements. Mean corrected QT interval (QTcF) greater than 470ms. Left ventricular ejection fraction (LVEF) <50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Mayo Clinic Cancer Center · Phoenix, Arizona
- University of California, San Diego · La Jolla, California
- University of Southern California · Los Angeles, California
- University Of California, Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06655246 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior prohibited medication, including investigational therapy disqualifies patients from enrollment.
Does this trial require KIT?
Yes, KIT mutation is a required biomarker for enrollment.
Are patients with KIT alterations eligible?
No. KIT t670x is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages